
FDA Director Responds to Drug Pricing Concerns
In response to the EpiPen pricing scandal, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, clarifies FDA’s role in drug pricing.
Drug pricing has become a hot topic after recent scandals about drug price increases, including the recent EpiPen price hike, have shocked consumers. In a Sept. 14, 2016
Woodcock specifically addressed the EpiPen price hike, stating that patents on the EpiPen, which extend to 2025, would delay the availability of generic versions of the drug. FDA is aware, Woodcock stated in the blog post, that the agency’s approval of generic versions of brand therapies may encourage competition and affect pricing.
“The good news is that the FDA has already
Because the agency is aware of the potential benefit of generics, FDA looks to review applications quickly. “To speed along the process, our Office of Generic Drugs prioritizes and expedites our review of applications for first generics, making sure that the first applicants to make a generic are moved to the head of the queue and given priority review,” Woodcock stated.
FDA has also created a “roadmap” to help develop new auto-injectors and provided manufacturers with
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.